Adient's third quarter of fiscal 2026, the period ended June 30, 2026 and reported August 5, 2026, was a print of solid volume growth but a margin disappointment that the headline number did not fully telegraph. Net sales reached $3,929 million, up five percent year-over-year, and adjusted EBITDA of $225 million matched the prior year quarter on a 30-basis-point margin contraction to 5.7 percent. The thesis here is that the operating margin is starting to roll over even as free cash flow inflects, and the gap between those two signals is the equity question for the next four quarters. We see the market pricing the company as a Chinese-OEM-exposed seat supplier with limited pricing power, and we read the latest quarter as confirming that read while showing a balance sheet that can absorb the cycle.
The mechanism behind our read is straightforward. Americas adjusted EBITDA grew 12 percent on a 10 percent revenue gain, the only segment that meaningfully compounded in the quarter, while EMEA adjusted EBITDA collapsed 33 percent on a four percent revenue decline and Asia adjusted EBITDA slipped 5 percent on a 12 percent revenue gain. The blended picture is a top-line story that looks healthier than the segment mix underneath it, and the company is using the cash it generates, including $138 million of free cash flow in the quarter and $161 million year-to-date, to fund $55 million of buybacks and prepare for a fourth-quarter settlement. The single load-bearing risk is that the EMEA deterioration is structural rather than cyclical, with the management narrative calling out overcapacity and pricing pressure in that region; the falsifiable clock is the fourth-quarter print in early November, which will show whether the EMEA margin stabilizes at the 1.2 percent level or trends toward 1.0 percent, and whether the IEEPA tariff refund benefit of roughly $52 million in Q3 repeats as a tailwind in Q4 or reverses.